EUVIMEDEUVIMED entdecken
Crossref

Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda

Janvier Serumondo, Peter Barebwanuwe, Ephrem Daniel Sheferaw iD, Jeannette Iyonizera, Charles Berabose iD, Sabine Umuraza, Calliope Ntuyenabo, Kelly Reine Kwizera, Donatha Dushimiyimana, Justine Umutesi iD, Jean Damascene Kabakambira, Bobo Buya und 5 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Janvier Serumondo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Rwanda Ministry of Health, Rwanda Biomedical Center, Kigali, Rwanda. Hauptthemen laut MEDLINE: Sofosbuvir, Antiviral Agents, Heterocyclic Compounds, 4 or More Rings, Ribavirin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: United Kingdom Federal, Commonwealth & Development Office, SHAPE, Rwandan government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C virus (HCV) retreatment in those who fail initial treatment but is unavailable in resource-limited settings. We describe a government sofosbuvir/velpatasvir + ribavirin (SOF/VEL + RBV) × 24 weeks retreatment program in Rwanda (November 2021–October 2022). Of 231 participants, 174 were cured (75.3% intention-to-treat analysis). SOF/VEL + RBV may be considered for HCV retreatment in resource-limited settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SofosbuvirAntiviral AgentsHeterocyclic Compounds, 4 or More RingsRibavirinCarbamatesHepatitis C, ChronicHepatitis CHumansMaleFemaleMiddle AgedRwandaAdultRetreatmentHepacivirusDrug Therapy, CombinationDrug CombinationsAgedBenzimidazolesBenzopyrans

Stichwörter der Autor:innen

Hepatitis C virus (HCV)cureretreatmentsecond linetreatment failure

Substanzen

SofosbuvirAntiviral AgentsHeterocyclic Compounds, 4 or More RingsRibavirinCarbamatesDrug Combinationssofosbuvir-velpatasvir drug combinationvelpatasvirBenzimidazolesBenzopyrans

Autor:innen und Institutionen

  • Rwanda Ministry of Health, Rwanda Biomedical Center, Kigali, Rwanda.
  • Clinton Health Access Initiative, Kigali, Rwanda.
  • Department of Internal Medicine, The University Teaching Hospital of Kigali, Kigali, Rwanda.
  • Clinton Health Access Initiative, Boston, Massachusetts, USA.

ORCID-Profile: Ephrem Daniel Sheferaw, Charles Berabose, Justine Umutesi, Caroline E Boeke, Christian B Ramers

Förderung

  • United Kingdom Federal, Commonwealth & Development Office
  • SHAPE
  • Rwandan government
  • Clinton Health Access Initiative

Zitieren

APA

Serumondo, J., Barebwanuwe, P., Sheferaw, E. D., Iyonizera, J., Berabose, C., Umuraza, S., Ntuyenabo, C., Kwizera, K. R., Dushimiyimana, D., Umutesi, J., Kabakambira, J. D., Buya, B., Azania, A., Boeke, C. E., Ngwije, A., Ramers, C. B., & Rwibasira, G. (2025). Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae637

Vancouver

Serumondo J, Barebwanuwe P, Sheferaw ED, Iyonizera J, Berabose C, Umuraza S, et al. Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae637

BibTeX
@article{Serumondo2025,
  author = {Serumondo, Janvier and Barebwanuwe, Peter and Sheferaw, Ephrem Daniel and Iyonizera, Jeannette and Berabose, Charles and Umuraza, Sabine and Ntuyenabo, Calliope and Kwizera, Kelly Reine and Dushimiyimana, Donatha and Umutesi, Justine and Kabakambira, Jean Damascene and Buya, Bobo and Azania, Amy and Boeke, Caroline E and Ngwije, Alida and Ramers, Christian B and Rwibasira, Gallican},
  title = {Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae637}
}
Kostenlos starten →